Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Acorda Therapeutics Inc    ACOR

 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
11/29/2016 11/30/2016 12/01/2016 12/02/2016 12/05/2016 Date
20.65(c) 20.8(c) 20.25(c) 20.3(c) 21.15 Last
1 572 387 509 902 519 982 434 733 123 538 Volume
+0.24% +0.73% -2.64% +0.25% +4.19% Change
More quotes
Financials ($)
Sales 2016 516 M
EBIT 2016 27,6 M
Net income 2016 -41,2 M
Finance 2016 40,4 M
Yield 2016 -
Sales 2017 542 M
EBIT 2017 -1,74 M
Net income 2017 -28,6 M
Debt 2017 7,04 M
Yield 2017 -
P/E ratio 2016 -
P/E ratio 2017
EV / Sales2016 1,74x
EV / Sales2017 1,74x
Capitalization 936 M
More Financials
Company
Acorda Therapeutics, Inc. develops and markets therapeutic products for nervous system disorders.The company's two main products are Ampyra and Zanaflex Capsules.The Ampyra is an oral drug, which treats to improve walking in patients with multiple sclerosis and Zanaflex Capsules, which is a short... 
More about the company
Surperformance© ratings of Acorda Therapeutics Inc
Trading Rating : Investor Rating :
More Ratings
Latest news on ACORDA THERAPEUTICS INC
12/01 ACORDA THERAPEUTICS : Patent Issued for Compositions and Methods for Treatment d..
12/01 ACORDA THERAPEUTICS : to Discontinue Development of Dalfampridine for Treatment ..
11/24 ACORDA THERAPEUTICS : Assigned Patent
11/22 ACORDA THERAPEUTICS : to Present at the 28th Annual Piper Jaffray Healthcare Con..
11/21 ACORDA THERAPEUTICS INC : Other Events, Financial Statements and Exhibits (form ..
11/21 ACORDA THERAPEUTICS : to Discontinue Development of Dalfampridine for Treatment ..
11/17 ACORDA THERAPEUTICS : to Present at the Stifel 2016 Healthcare Conference
11/09 ACORDA THERAPEUTICS : to Present at the Stifel 2016 Healthcare Conference
11/07 ACORDA THERAPEUTICS : Management's Discussion and Analysis of Financial Conditio..
11/03 ACORDA THERAPEUTICS : Provides Financial and Pipeline Update for Third Quarter 2..
More news
Sector news : Bio Therapeutic Drugs
12/03DJJOHNSON & JOHNSON : Boosts Actelion Bid -Bloomberg
12/02 Pharma execs weigh in on possible changes under Trump
11/30 ACTELION : Rejecting J&J could leave Actelion with 'lot of explaining to do'
11/28 Actelion's ambitious independent-minded CEO will drive up takeover price
11/26DJWHAT'S NEWS : Business & Finance -- WSJ
More sector news : Bio Therapeutic Drugs
News from SeekingAlpha
11/21 Acorda nixes development of dalfampridine for PSWD after failed late-stage st..
10/27 Acorda Therapeutics, Inc. 2016 Q3 - Results - Earnings Call Slides
10/27 Acorda Therapeutics' (ACOR) CEO Ron Cohen on Q3 2016 Results - Earnings Call ..
10/27 Acorda Therapeutics misses by $0.15, beats on revenue
10/26 Notable earnings before Thursday?s open
Advertisement
Chart ACORDA THERAPEUTICS INC
Duration : Period :
Acorda Therapeutics Inc Technical Analysis Chart | ACOR | US00484M1062 | 4-Traders
Full-screen chart
Technical analysis trends ACORDA THERAPEUTI...
Short TermMid-TermLong Term
TrendsBullishNeutralBearish
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 8
Average target price 35,7 $
Spread / Average Target 76%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Ronald Cohen President, Chief Executive Officer & Director
David Lawrence Chief Financial & Accounting Officer
Andrew R. Blight Chief Scientific Officer
Anthony O. Caggiano Vice President-Research & Development
Richard P. Batycky Chief Technology Officer
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
ACORDA THERAPEUTICS IN..-52.55%936
AMGEN, INC.-11.29%107 132
GILEAD SCIENCES, INC.-28.02%95 410
CELGENE CORPORATION-1.78%91 187
REGENERON PHARMACEUTIC..-31.34%39 310
ACTELION LTD40.40%21 739
More Results